Literature DB >> 21296602

Imputing QALYs from single time point health state descriptions on the EQ-5D and the SF-6D: a comparison of methods for hepatitis a patients.

Jeroen Luyten1, Christiaan Marais, Niel Hens, Koen De Schrijver, Philippe Beutels.   

Abstract

OBJECTIVES: To explore the impact of applying different non-standardized analytical choices for quality of life measurement to obtain quality-adjusted life years (QALYs). In addition to more widely discussed issues such as the choice of instrument (e.g. EQ-5D or SF-6D?) researchers must also choose between different recall periods, scoring algorithms and interpolations between points of measurement.
METHODS: A prospective survey was made among 114 Belgian patients with acute hepatitis A illness. Using non-parametric tests and generalized linear models (GLM's), we compared four different methods to estimate QALY losses, two based on the EQ-5D (administered during the period of illness without recall period) and two based on the SF-6D (administered after illness with 4 weeks recall period).
RESULTS: We found statistically significant differences between all methods, with the non-parametric SF-6D-based method yielding the highest median QALY impact (0.032 QALYs). This is more than five times as high as the EQ-5D-based method with linear health improvement, which yields the lowest median QALY impact (0.006 QALYs).
CONCLUSIONS: Economic evaluations of health care technologies predominantly use QALYs to quantify health benefits. Non-standardised analytical choices can have a decision-changing impact on cost-effectiveness results, particularly if morbidity takes up a substantial part of the total QALY loss. Yet these choices are rarely subjected to sensitivity analysis. Researchers and decision makers should be aware of the influence of these somewhat arbitrary choices on their results.
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21296602     DOI: 10.1016/j.jval.2010.10.004

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  4 in total

1.  Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach.

Authors:  Wail A Hayajneh; Vincent J Daniels; Cerise K James; Muhammet Nabi Kanıbir; Matthew Pilsbury; Morgan Marks; Michelle G Goveia; Elamin H Elbasha; Erik Dasbach; Camilo J Acosta
Journal:  BMC Infect Dis       Date:  2018-03-07       Impact factor: 3.090

2.  Establishing the Socio-Economic Impact of Degenerative Cervical Myelopathy Is Fundamental to Improving Outcomes [AO Spine RECODE-DCM Research Priority Number 8].

Authors:  Benjamin M Davies; Richard Phillips; David Clarke; Julio C Furlan; Andreas K Demetriades; Jamie Milligan; Christopher D Witiw; James S Harrop; Bizhan Aarabi; Shekar N Kurpad; James D Guest; Jefferson R Wilson; Brian K Kwon; Alexander R Vaccaro; Michael G Fehlings; Vafa Rahimi-Movaghar; Mark R N Kotter
Journal:  Global Spine J       Date:  2022-02

3.  Health economic assessment of universal immunization of toddlers against Hepatitis A Virus (HAV) in Mexico.

Authors:  Fernando Carlos; Jorge Alberto Gómez; Pablo Anaya; Luis Romano-Mazzotti
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

4.  An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence.

Authors:  Rachid Rafia; Peter J Dodd; Alan Brennan; Petra S Meier; Vivian D Hope; Fortune Ncube; Sarah Byford; Hiong Tie; Nicola Metrebian; Jennifer Hellier; Tim Weaver; John Strang
Journal:  Addiction       Date:  2016-05-06       Impact factor: 6.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.